Alkermes Schizophrenia Drug Aristada Wins FDA Nod
This article was originally published in Scrip
Executive Summary
After the U.S. markets closed on Oct. 5, Alkermes plc revealed it had gained the FDA's approval to market Aristada (aripiprazole lauroxil) extended-release injectable suspension as a treatment for schizophrenia.